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A synthesized mouse vasoactive intestinal contractor peptide, which belongs to a novel member of the endothelin family, 
induced a prolonged contraction in mouse ileum as well as porcine coronary artery in vitro. Studies comparing the effects 
of vasoactive intestinal contractor and endothelin on different tissues revealed that the maximum ileum contraction of 
vasoactive intestinal contractor was much higher than that of endothelin in both guinea pig and mouse systems, but that 
the vasoconstriction activity of vasoactive intestinal contractor was weaker than that of endothelin in porcine artery. 
These resuts show that vasoactive intestinal contractor might be a novel gastrointestinal hormone. 
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1. INTRODUCTION 
A growing number of regulatory peptides have 
been newly identified by using gastrointestinal con- 
traction as a non-specific assay for detecting un- 
known neuropeptides from various tissues. How- 
ever, only a few of the cases reported have been 
genuine gastrointestinal hormones in respect of 
their expression sites and activities. Vasoactive in- 
testinal polypeptide (VIP), isolated from porcine 
intestine, has biological actions including vasodila- 
tion and relaxant activity on the gastrointestinal 
system [I ,2]. Cholecystokinin, a substance that 
caused contraction of the gall bladder, was isolated 
from duodenal mucosa [3,4]. Motilin, a 22-amino 
acid polypeptide isolated from porcine gut, 
stimulates fundus contraction [5]. 
Recently, we found a structurally related endo- 
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thelin family (unpublished). The endothelin family 
consists, at present, of three peptides: endothelin 
[6], vasoactive intestinal contractor (VIC), and en- 
dothelin homologous peptide [7]. Endothelin (ET) 
is an endothelial cell derived vasoconstrictor pep- 
tide [6,8], which consists of 21 amino acid residues 
with 2 sets of intrachain disulfide-bonds. The novel 
peptide, WC, which differs from ET in 3 amino 
acid residues (nos. 4, 6, 7 in 21 residues), has been 
cloned and sequenced from the mouse genome by 
us. Then the position of the cysteine residues was 
perfectly conserved in the VIC; in vivo pressor ac- 
tivities of synthetic VIC were confirmed as those of 
ET. Furthermore, Northern blot hybridization in- 
dicated that the VIC probe hybridized with a 
transcript in mouse intestine, but not in other 
mouse tissues or endothelial cells (Saida, K., Mit- 
sui, Y. and Ishida, N., unpublished). 
To investigate the activity of this novel peptide, 
VIC, we have studied the contractile effect of syn- 
thetic VIC on isolated mouse and guinea pig ileum, 
and porcine coronary artery, and compared its ef- 
fect with that of endothelin. Here we show that 
VIC has a stronger effect on intestine contraction 
than ET and that VIC is a much less potent 
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vasoconstrictor than ET. In the presence of a Ca2+ 
channel blocker, VIC- and ET-induced contrac- 
tions of guinea pig ileum are inhibited. These 
results are discussed in conjugation with the role of 
VIC as a gastrointestinal hormone and its 
biological actions. 
2. MATERIALS AND METHODS 
2.1. Synthesis of VIC 
According to the primary structure predicted from the 
nucleotide sequence, WC was made using a solid-phase peptide 
synthesizer. The purity of the final product was checked by 
analytical HPLC and amino acid analysis. The disulfide-bond 
topology of synthetic WC was the same as ET, judging from 
HPLC profiles. 
2.2. Assay of in vitro vasoconstriction 
Right and left coronary arteries were isolated from adult por- 
cine hearts, which were brought in ice from a slaughter house 
within 2 h of being killed. Parts of coronary arteries were cut in- 
to 2 x 10 mm helical strips with the intima denuded by being 
rubbed with a small swab, and suspended in 5 ml glass chambers 
filled with Krebs-Henseleit solution (118 [mM] NaCl, 4.7 KCl, 
2.5 CaC12, 1.2 KH~P04,25 NaHCOa, 1.2 MgS04, 10 glucose) at 
37°C and gassed with 95% 02/5% COz. Arterial strips were 
equilibrated at a passive tension of 2 g for 12 h. The constric- 
tion was measured as the increase in isometric tension with 
force-displacement transducers (model VL-10 CR, Minebea 
Co., Ltd). 
2.3. Assay of in vitro ileum contraction 
The animals used were mice (ICR, male) and guinea pigs 
(male). The ileum samples were prepared by cutting out the tract 
about 10 cm upstream from the cecum. Ilea, obtained from 
nonfasted and decapitated animals were immediately suspended 
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Fig. 1. Comparison of dose-dependent constrictive responses of 
isolated aortic strips to synthetic ET (n = 7) (0) and VIC (n = 5) 
(8). Each point shows the mean f SE. Vertical axis shows 
percentages compared to the maximum tension of 60 mM KCl- 
induced constrictions. 
in a siliconized organ bath (25 ml) that contained a modified 
Tyrode solution (136.8 [mM] NaCl, 2.7 KCl, 1.8 CaC12, 1 .O 
MgCl2, 0.4 NaHP04, 11.9 NaHCO3 and 5.5 glucose) at 37°C 
(mouse) and 27°C (guinea pig). One end was attached to a rigid 
support and the free end to a lever connected via a spring to a 
force-displacement transducer for measuring contractions. The 
load on the ileum was set at 0.5 g. The solution was bubbled 
with 95% 02 and 5% COZ. The tissues were allowed to 
equilibrate for about 1 h and regular contractions were elicited 
by 10m6 M acetylcholine (mouse) and lo-’ M acetylcholine 
(guinea pig). The magnitude of a contraction was expressed as a 
percentage of the 10m5 M acetylcholine (mouse) and 10e6 M 
acetylcholine (guinea pig)-induced contraction (100%). 
3. RESULTS 
3.1. A comparison of vasoconstriction caused by 
VIC and ET 
Despite the slow onset, the long lasting vasocon- 
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Fig.2. Comparison of dose-dependent contractile ffects of WC 
(0) and endothelin (8) on mouse ileum. Each point represents 
the mean + SE (n = 3). The magnitude of a contraction was ex- 
pressed as a percentage of the 10e5 M acetylcholine-induced 
contraction. 
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with that of synthetic ET on porcine coronary 
artery strips in vitro, the maximum tension caused 
by ET was much higher than that caused by VIC. 
In addition, the estimated EC& value of ET (3.5 x 
10m8 M) was lower than that of VIC (4.8 x 
lo-’ M). These results indicate that VIC is a much 
less potent vasoconstrictor than ET in porcine 
artery. 
3.2. A comparison of ileum contraction caused by 
VIC and ET 
A comparison of dose-response contraction in 
mouse ileum caused by VIC and ET is shown in 
fig.2. The estimated EC50 value of VIC and ET was 
almost the same: 8.4 x 10m9 M and 7.2 x 10s9 M, 
respectively. But, the maximum VIC contraction 
was 1.8 times higher than the maximum ET con- 
traction, i.e. 49.3 f 9.5% (10e6 M VIC) and 
31.1 f 3.9% (+ SE) (10e6 M ET), respectively. 
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Fig.3. Comparison of dose-dependent contractile ffects of WC Fig.4. Inhibition of guinea pig ileum contraction by Ca2+ chan- 
(0) and endothelin (m) on guinea pig ileum. Each point shows nel blocker (10e6 M nilvadipine [9]) to lo-* M ET and lo-’ M 
the mean f SE (n = 3). The contraction was expressed as a VIC. Each bar indicates the ‘7’0 contraction which represents the 
percentage of the 10v6 M acetylcholine-induced contraction. mean f SE (n = 3). 
The same contractile profile of VIC and ET was 
also observed in guinea pig ileum, as shown in 
fig.3. The estimated EC50 values in the guinea pig 
assay of VIC and ET were 3.5 x 10e9 M and 4.0 x 
10m9 M, respectively, but the maximum contrac- 
tions of these two peptides were very distinctive, 
i.e. 84.6 f 2.1% (10m7 M VIC) and 65.9 + 1.4% 
(10m7 M ET). These data show that VIC is a much 
more potent contractor than ET in both guinea pig 
and mouse ileum. The slow-onset, long lasting il- 
eum contractor activity of synthetic VIC is very 
similar to the vasoconstriction activity of synthetic 
ET and VIC in porcine coronary artery strips in 
vitro. About 40 min was required after contraction 
for ileum to return to the base-line levels. Little 
transient relaxation was caused by VIC input, but 
the biological significance of this phenomenon is 
unclear. VIC-induced contraction was also 
characteristically difficult to wash out. The max- 
imal contraction of both 10m8 M VIC and 10v8 M 
ET at the same time was almost the same level as 
the mean magnitude of each substance-induced 
contraction separately (not shown). 
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3.3. Inhibition of Ca’* channel blocker 
Nilvadipine (Fujisawa Pharmaceutical Co., 
Ltd), a derivative of nifedipine, is a new Ca2+ 
channel blocker [9]. In the presence of 10m6 M 
nilvadipine, ET and VIC-induced contractions of 
guinea pig ilea were attenuated to a level of about 
5070, as shown in fig.4. 
4. DISCUSSION 
VIC was found to have a much stronger contrac- 
tile activity in mouse and guinea pig ileum than ET, 
but VIC was found to be a less potent vasoconstric- 
tor in porcine coronary artery than ET. In addi- 
tion, a transcript of this peptide gene was not de- 
tectable in endothelial cells, but was detected in the 
mouse intestine (Saida, K., Mitsui, Y. and Ishida, 
N., unpublished). Thus, this novel peptide might 
be classified as a gastrointestinal hormone. Then 
we propose designating it, ‘VIC’, i.e., vasoactive 
intestinal contractor. The fact that VIC and ET 
had differential contractile activities on rodent il- 
eum and porcine coronary artery, suggests a 
possibility that minor difference in their receptors 
may exist in ileum and in vascular smooth muscle 
cells. However, we have previously shown that a 
transcript of ET is expressed in endothelial cells, 
but not in the intestine, while a transcript of VIC is 
expressed in the intestine, but not in endothelial 
cells (unpublished), prompting a hypothesis that 
the biological role of VIC and ET are distinguished 
by tissue-specific transcription of a ligand gene in 
vivo. 
An inhibition experiment in the presence of a 
Ca2+ channel blocker (nilvadipine [9]) suggests that 
an influx of extracellular Ca2+ is required for the il- 
eum contraction effect of VIC and ET. 
The question as to whether VIC acts on a unique 
receptor in the intestine which is distinct from the 
ET receptor in vascular smooth muscle cells re- 
mains to be clarified. VIC’s physiological roles in 
the gastrointestinal tract and other organs, as well 
as in the central and peripheral nervous systems, 
also remain to be determined. 
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